Ragaglitazar

CAS No. 222834-30-2

Ragaglitazar( —— )

Catalog No. M34389 CAS No. 222834-30-2

Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1302 In Stock
25MG 2119 In Stock
50MG 2585 In Stock
100MG 3441 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ragaglitazar
  • Note
    Research use only, not for human use.
  • Brief Description
    Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
  • Description
    Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    222834-30-2
  • Formula Weight
    419.47
  • Molecular Formula
    C25H25NO5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(COC1=CC=C(C[C@H](OCC)C(O)=O)C=C1)N2C=3C(OC=4C2=CC=CC4)=CC=CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003;140(3):527-537. ?
molnova catalog
related products
  • Ankaflavin

    Ankaflavin, isolated from Monascus-Fermented red rice, is a PPARγ agonist with anti-inlfammatory activity.

  • AZD2461

    AZD2461 is a novel PARP inhibitor.

  • LY518674

    LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis.